Marika Guercio | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma	CLINICAL CANCER RESEARCH	2024
GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma	CLINICAL CANCER RESEARCH	2024
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.	THE NEW ENGLAND JOURNAL OF MEDICINE	2023
Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies	NATURE COMMUNICATIONS	2023
Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies	NATURE COMMUNICATIONS	2023
Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy	FRONTIERS IN IMMUNOLOGY	2023
T-Cell Defects Associated to Lack of Spike-Specific Antibodies after BNT162b2 Full Immunization Followed by a Booster Dose in Patients with Common Variable Immune Deficiencies	CELLS	2022
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia	JOURNAL OF HEMATOLOGY & ONCOLOGY	2022
B Cell Response Induced by SARS-CoV-2 infection Is boosted by the BNT162b2 vaccine in primary antibody deficiencies	CELLS	2021
SARS-CoV-2 vaccine induced atypical immune responses in antibody defects. Everybody does their best	JOURNAL OF CLINICAL IMMUNOLOGY	2021
CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells	HAEMATOLOGICA	2020
Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B cell precursor acute lymphoblastic leukemia	LEUKEMIA	2019
Adoptive immunotherapy using prame-specific t cells in medulloblastoma	CANCER RESEARCH	2018
Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma	ONCOIMMUNOLOGY	2018